CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point
CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
From: Evidence-based recommendations for the use of continuous glucose monitoring in type 2 diabetes: the Italian guidelines (Acta Diabetol, 2026 Aug) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 86, 85, 105, 142, 121.
New guidelines and consensus this year
- 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetesDiabetologia2026 Sep 15
- Evidence-based recommendations for the use of continuous glucose monitoring in type 2 diabetes: the Italian guidelinesActa Diabetol2026 Aug
- The use of technology in diabetes in pregnancy: a position statement of expert opinion from the association of medical diabetologists (AMD), the Italian society of diabetology (SID) and the interassociative diabetes and pregnancy study groupActa Diabetol2026 Jun
- [Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology]Gynecol Obstet Fertil Senol2026 Mar
- Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statementLancet Diabetes Endocrinol2026 Feb
All papers from the last 12 months
589 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Real-time continuous glucose monitoring in adults with type 2 diabetes managed with non-intensive insulin regimens: impact on glycemia and self-managementJ Diabetes Metab Disord2026 DecPMID 42327989
- Episodic hypercortisolemia-mediated periods of worsening hyperglycemia in cyclic Cushing syndromeJCEM Case Rep2026 NovPMID 42798868
- Person-Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin-Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo-METRICS StudyDiabetes Obes Metab2026 NovPMID 42677701
- Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA)Diabetologia2026 NovPMID 42618811RCT
- Vegetable-First Meal Sequence Suppresses Postprandial Glycaemic Excursions and Variability in Young Women With High-Risk Phenotype for Early-Onset Type 2 Diabetes: A 4-Arm Randomized Crossover Trial With Continuous Glucose MonitoringDiabetes Obes Metab2026 NovPMID 42608327RCT
- Continuous Glucose Monitoring Systems in Europe: Regulatory Landscape and Certification Process Challenges Under MDR 2017/745Diabetes Obes Metab2026 NovPMID 42595726Review
- Community-Based Personalised Lifestyle Intervention Guided by Intermittent Continuous Glucose Monitoring in Adults With Type 2 Diabetes: A Multicentre Randomised Controlled TrialDiabetes Obes Metab2026 NovPMID 42587354RCT
- Predictive Modelling of 3-Month Glycemic Target Achievement in Type 2 Diabetes Mellitus Using Artificial Intelligence and Continuous Glucose Monitoring: A Retrospective Cohort StudyDiabetes Obes Metab2026 NovPMID 42581435
- It's a game changer in terms of diabetic management': A qualitative study of adolescents' and parents' experiences of a 6-month trial of continuous glucose monitoring in type 2 diabetesDiabet Med2026 NovPMID 42487247
- Continuous Glucose Monitoring in Older-Old With Type 2 Diabetes Mellitus: A Narrative Review of Evidence and RecommendationsDiabetes Obes Metab2026 NovPMID 42472682Review
More endocrinology trends
All specialties →Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point: Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
Cell therapy for type 1 diabetes
Islet transplantation and stem cell-derived beta cells.
Delaying type 1 diabetes
Teplizumab and other immunotherapy to delay type 1 diabetes.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("continuous glucose monitor*"[tiab] OR CGM[tiab]) AND "type 2 diabetes"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.